Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics

Adaptive Design for Phase II/III Platform Trial of Lassa Fever Therapeutics

The current recommendation for treating Lassa fever with ribavirin is supported only by weak evidence. Given the persistent effects in areas with endemic transmission and epidemic potential, there is an urgent need to reassess ribavirin and investigate other potential therapeutic candidates; howeve...

Full description

Bibliographic Details
Main Authors: Josephine Bourner, Michel Vaillant, Alex Paddy Abdel Salam, Marie Jaspard, Camille Fritzell, Shevin T. Jacob, Tom E. Fletcher, Michael Ramharter, Nnennaya Ajayi, Sylvanus Okogbenin, Cyril Erameh, Donald Grant, Robert Samuels, Oladele Oluwafemi Ayodeji, Armand Sprecher, Bronner P. Gonçalves, Tansy Edwards, Piero Olliaro
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2025-02-01
Series:Emerging Infectious Diseases
Subjects:
Lassa fever
clinical trials
viruses
phase II/III multicenter randomized controlled platform trial
Online Access:https://wwwnc.cdc.gov/eid/article/31/2/24-0251_article

Internet

https://wwwnc.cdc.gov/eid/article/31/2/24-0251_article

Similar Items